Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: GLP-1 RA Group in Adults with type 2 diabetes

Page standards status: Informative

Raw xml | Download


<Group xmlns="http://hl7.org/fhir">
  <id value="557341"/>
  <meta>
    <versionId value="3"/>
    <lastUpdated value="2026-08-06T17:15:59.259Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/comparator-group"/>
  </meta>
  <language value="en"/>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml">
  <table class="narrative-table">
    <tbody>
<tr>


<th colspan="2" scope="row" class="row-header"><a name="metadata"> </a>Metadata</th>


</tr>

<tr>


<th scope="row" class="row-header">Title</th>



<td class="content-container">GLP-1 RA Group in Adults with type 2 diabetes</td>


</tr>













  
<tr>


<th scope="row" class="row-header">Identifier</th>



<td class="content-container">557341</td>


</tr>
















<tr>


<th scope="row" class="row-header">Use Context</th>



<td class="content-container">
    Evidence Communication

 = 
    ComparatorGroup


</td>


</tr>














<tr>


<th scope="row" class="row-header">Steward (Publisher)</th>



<td class="content-container">Computable Publishing LLC</td>


</tr>











<tr>


<th scope="row" class="row-header">Description</th>



<td class="content-container"><div><p>Glucagon-Like Peptide-1 (GLP-1) receptor agonists</p>
</div></td>


</tr>



<tr>


<th scope="row" class="row-header">Copyright</th>



<td class="content-container"><div><p>Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).</p>
</div></td>


</tr>











<tr>


<th scope="row" class="row-header">Type</th>



<td class="content-container">Person</td>


</tr>







































<tr>
  <th colspan="2" scope="row" class="row-header">Generated using version 0.5.6 of the sample-content-ig Liquid templates</th>
</tr>

    </tbody>
  </table>
</div>
  </text>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Computable Publishing®: MAGIC-to-FEvIR Converter"/>
    </valueContactDetail>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
    <valueRelatedArtifact>
      <type value="part-of"/>
      <resourceReference>
        <type value="Composition"/>
        <identifier>
          <type>
            <text value="FEvIR Linking Identifier"/>
          </type>
          <system value="https://fevir.net/FLI"/>
          <value value="MAGIC-5288-j1Wqrn-conversion-report"/>
          <assigner>
            <display value="Computable Publishing LLC"/>
          </assigner>
        </identifier>
        <display
                 value="MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"/>
      </resourceReference>
    </valueRelatedArtifact>
  </extension>
  <extension
             url="http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status">
    <valueCodeableConcept>
      <coding>
        <system
                value="http://terminology.hl7.org/CodeSystem/cited-artifact-status-type"/>
        <code value="active"/>
        <display value="Active"/>
      </coding>
    </valueCodeableConcept>
  </extension>
  <extension url="http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as">
    <valueMarkdown
                   value="GLP-1 RA Group in Adults with type 2 diabetes [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557341. Revised 2026-08-06. Available at: https://fevir.net/resources/Group/557341. Computable resource at: https://fevir.net/resources/Group/557341#json."/>
  </extension>
  <url value="https://fevir.net/resources/Group/557341"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="https://fevir.net/FOI"/>
    <value value="557341"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <identifier>
    <type>
      <text value="FEvIR Linking Identifier"/>
    </type>
    <system value="https://fevir.net/FLI"/>
    <value
           value="MAGIC-5288-j1Wqrn-comparator-group-MAGIC-5288-j1Wqrn-compa-85798"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <title value="GLP-1 RA Group in Adults with type 2 diabetes"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description value="Glucagon-Like Peptide-1 (GLP-1) receptor agonists"/>
  <useContext>
    <code>
      <system value="https://fevir.net/resources/CodeSystem/179423"/>
      <code value="evidence-communication"/>
      <display value="Evidence Communication"/>
    </code>
    <valueCodeableConcept>
      <coding>
        <system value="https://fevir.net/resources/CodeSystem/179423"/>
        <code value="ComparatorGroup"/>
        <display value="ComparatorGroup"/>
      </coding>
    </valueCodeableConcept>
  </useContext>
  <copyright
             value="Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse)."/>
  <type value="person"/>
  <membership value="enumerated"/>
  <combinationMethod value="all-of"/>
  <characteristic>
    <code>
      <text value="Member of"/>
    </code>
    <valueReference>🔗 
      <reference value="Group/236947"/>
      <type value="Group"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-population-group-85394-85798"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display value="Adults with type 2 diabetes and CVD and CKD"/>
    </valueReference>
    <exclude value="false"/>
    <description value="inclusion in Adults with type 2 diabetes"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Exposed to"/>
    </code>
    <valueReference>🔗 
      <reference value="Group/236776"/>
      <type value="Group"/>
      <identifier>
        <type>
          <text value="FEvIR Linking Identifier"/>
        </type>
        <system value="https://fevir.net/FLI"/>
        <value value="MAGIC-5288-j1Wqrn-comparator-85394-C-85798"/>
        <assigner>
          <display value="Computable Publishing LLC"/>
        </assigner>
      </identifier>
      <display value="Glucagon-Like Peptide-1 (GLP-1) receptor agonists"/>
    </valueReference>
    <exclude value="false"/>
    <description value="received GLP-1 RA"/>
  </characteristic>
</Group>